ReviewAdvanced healthcare materials2026
Current Challenges in Hemostasis and Advances in Particle-Assisted Styptic Devices.
Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioorthogonally Cross-Linked Injectable PEG Hydrogel with Robust Hemostatic and Antibacterial Properties.Gels (Basel, Switzerland) · 2026Article
- Current Challenges in Hemostasis and Advances in Particle-Assisted Styptic Devices.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rapid and effective hemorrhage control is critical in trauma and surgical interventions, where uncontrolled bleeding remains a leading cause of preventable death. In response to this urgent clinical demand, the development of novel hemostatic materials is the focus of increasing research interest, in both academia and industry. Styptic dressings are gradually evolving to address this need. However, significant challenges, such as delayed activation, suboptimal performance in severe conditions, and biocompatibility issues, persist. Here current limitations in hemostatic dressing technologies are explored, and recent innovations including biomimetic approaches in this field are highlighted. Special emphasis is placed on microparticle-integrated and nanoengineered systems integrated with drug delivery technologies. By addressing these challenges, it is aimed to inspire new pathways for the development of next-generation multifunctional dressings with enhanced efficacy and accessibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.